Venerated and Vital: Using Lipid Based Delivery for Fast and Efficient Early Phase Development, Upcoming Webinar Hosted by Xtalks

Press Release (ePRNews.com) - TORONTO - Sep 28, 2018 - In a live session on Tuesday, October 16, 2018 at 11 a.m. EDT (4 p.m. BST/UK), viewers can learn how to apply lipid-based drug delivery systems to early phase molecules by joining academic and industry experts to develop a better understanding of new prediction models, novel lipid excipients, and lipid formulation screening tools with real-world case studies.

Introduced to the pharmaceutical industry decades ago, lipid-based drug delivery systems are the most well-studied and widely utilized technology among all available bioavailability enhancement technologies.1 Lipid-based drug delivery systems have delivered more than 60 unique drug molecules to market – and counting.2

With today’s increasingly complex new molecules emerging from R&D, optimizing bioavailability for early phase molecules is critical to their success. Not only do lipid-based drug delivery systems provide a reliable solution for poorly soluble molecules, they also allow for efficient and scalable dose formulation solutions which can accelerate progress to clinic and beyond, especially for orphan and breakthrough therapies.

Learning objectives:

  • Understand the importance of and recent developments in lipid-based drug delivery systems
  • Learn about novel lipid excipients, models, and screening tools for early phase development of lipid-based drug delivery systems
  • Learn how to use mechanistic studies and modeling to predict the impact of lipids on oral absorption

Join the panel of experts including Nigel Langley, Director Technical Service and Scientific Affairs at BASF Pharma Solutions, Stephen Tindal, Director of Science & Technology, USA, at Catalent, and Rebecca L. Carrier, Professor & Associate Chair of Research, Chemical Engineering Department, Northeastern University, for an interactive session.

The presentation is designed to benefit professionals working within early phase development, including formulation scientists, pharmaceutical development scientists, and those working within pharmaceutical technology, pharmaceutical R&D, formulation development, product development and CMC.

For more information about this complimentary event, visit: Venerated and Vital: Using Lipid Based Delivery for Fast and Efficient Early Phase Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar

Contact:

Nima Rajan

Tel: +1 (416) 977-6555 ext 352

Email: nrajan@xtalks.com

References:

1: Review and analysis of FDA approved drugs using lipid-based formulations, DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2017

2: Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market, DRUG DEVELOPMENT AND DELIVERY, September 2016 Vol 16 No 7

Source : Xtalks
Business Info :
Xtalks

You may also like this  

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login

DISCLAIMER

If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.